Stock listing
Frankfurt:83B 3SBio, Inc. Aktie
German listing (Frankfurt) of 3SBio, Inc. · home listing HKEX:1530
Follow 3SBio, Inc. into a list and get an email when it puts out news.
Share price · FWB:83B
€1.44 EUR -0.03 (-2.0%)
Close on Nov 20, 2026
- Day range
- €1.44 – €1.44 EURNov 20, 2026
- Market cap
- €3.58B EURAt the close on Nov 20, 2026 · price × 2.48B shares outstanding
- 52-week range
- €1.44 – €3.53 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,053 EURMedian day 0 shares · 43 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:1530 · Home | $12.71 HKD | -0.59 (-4.4%) | 15,783,742 | $13.12 | $13.12 | $12.48 | $13.30 | Close on Nov 20, 2026 |
| OTC:TRSBF | $1.82 USD | 0.00 (0.0%) | — | $1.82 | $1.82 | $1.82 | $1.82 | Close on Nov 17, 2026 |
| Frankfurt:83B | €1.445 EUR | -0.029 (-2.0%) | — | €1.439 | €1.445 | €1.439 | €1.474 | Close on Nov 20, 2026 |
| Munich:83B | €1.523 EUR | -0.056 (-3.5%) | — | €1.523 | €1.523 | €1.523 | €1.579 | Close on Nov 20, 2026 |
| Dusseldorf:83B | €1.457 EUR | -0.03 (-2.0%) | — | €1.438 | €1.457 | €1.438 | €1.487 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:83B · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.697 | +0.039 | +2.4% | €1.696 | €1.71 | €1.691 | 0 | |
| €1.658 | +0.01 | +0.6% | €1.708 | €1.729 | €1.65 | 0 | |
| €1.648 | +0.105 | +6.8% | €1.652 | €1.655 | €1.648 | 0 | |
| €1.543 | -0.029 | -1.8% | €1.547 | €1.567 | €1.543 | 8,804 | |
| €1.572 | +0.071 | +4.7% | €1.536 | €1.594 | €1.519 | 0 | |
| €1.501 | -0.067 | -4.3% | €1.507 | €1.523 | €1.485 | 0 | |
| €1.568 | +0.043 | +2.8% | €1.551 | €1.577 | €1.551 | 12,000 | |
| €1.525 | +0.064 | +4.4% | €1.525 | €1.526 | €1.521 | 7,000 | |
| €1.461 | -0.093 | -6.0% | €1.463 | €1.463 | €1.455 | 0 | |
| €1.554 | -0.01 | -0.6% | €1.56 | €1.563 | €1.55 | 1,136 | |
| €1.564 | +0.066 | +4.4% | €1.57 | €1.57 | €1.555 | 142 | |
| €1.498 | -0.085 | -5.4% | €1.50 | €1.501 | €1.49 | 0 | |
| €1.583 | -0.026 | -1.6% | €1.592 | €1.594 | €1.568 | 0 | |
| €1.609 | +0.061 | +3.9% | €1.609 | €1.609 | €1.609 | 0 | |
| €1.548 | -0.075 | -4.6% | €1.548 | €1.548 | €1.548 | 0 | |
| €1.623 | +0.042 | +2.7% | €1.623 | €1.623 | €1.623 | 0 | |
| €1.581 | -0.021 | -1.3% | €1.581 | €1.581 | €1.581 | 0 | |
| €1.602 | -0.021 | -1.3% | €1.602 | €1.602 | €1.602 | 0 | |
| €1.623 | -0.087 | -5.1% | €1.623 | €1.623 | €1.623 | 0 | |
| €1.71 | +0.046 | +2.8% | €1.67 | €1.72 | €1.66 | 1,146 | |
| €1.664 | -0.095 | -5.4% | €1.664 | €1.664 | €1.664 | 360 | |
| €1.759 | +0.035 | +2.0% | €1.674 | €1.765 | €1.653 | 360 | |
| €1.724 | -0.038 | -2.2% | €1.725 | €1.725 | €1.723 | 0 | |
| €1.762 | +0.069 | +4.1% | €1.766 | €1.772 | €1.759 | 0 | |
| €1.693 | -0.048 | -2.8% | €1.724 | €1.731 | €1.692 | 0 | |
| €1.741 | -0.025 | -1.4% | €1.741 | €1.741 | €1.741 | 2 | |
| €1.766 | -0.025 | -1.4% | €1.766 | €1.766 | €1.766 | 0 | |
| €1.791 | +0.079 | +4.6% | €1.791 | €1.791 | €1.791 | 0 | |
| €1.712 | +0.013 | +0.8% | €1.712 | €1.712 | €1.712 | 0 | |
| €1.699 | -0.028 | -1.6% | €1.699 | €1.699 | €1.699 | 0 | |
| €1.727 | -0.046 | -2.6% | €1.727 | €1.727 | €1.727 | 0 | |
| €1.773 | -0.067 | -3.6% | €1.773 | €1.773 | €1.773 | 0 | |
| €1.84 | +0.028 | +1.5% | €1.845 | €1.845 | €1.839 | 0 | |
| €1.812 | -0.027 | -1.5% | €1.814 | €1.82 | €1.805 | 0 | |
| €1.839 | +0.111 | +6.4% | €1.851 | €1.853 | €1.83 | 0 | |
| €1.728 | -0.008 | -0.5% | €1.728 | €1.728 | €1.728 | 2,148 | |
| €1.736 | +0.049 | +2.9% | €1.736 | €1.736 | €1.736 | 0 | |
| €1.687 | -0.039 | -2.3% | €1.687 | €1.687 | €1.687 | 0 | |
| €1.726 | -0.001 | -0.1% | €1.726 | €1.726 | €1.726 | 0 | |
| €1.727 | +0.073 | +4.4% | €1.727 | €1.727 | €1.727 | 0 | |
| €1.654 | +0.013 | +0.8% | €1.654 | €1.654 | €1.654 | 1,016 | |
| €1.641 | -0.057 | -3.4% | €1.646 | €1.646 | €1.63 | 0 | |
| €1.698 | -0.047 | -2.7% | €1.715 | €1.716 | €1.686 | 0 | |
| €1.745 | +0.041 | +2.4% | €1.745 | €1.745 | €1.745 | 0 | |
| €1.704 | -0.001 | -0.1% | €1.727 | €1.728 | €1.702 | 0 | |
| €1.705 | -0.028 | -1.6% | €1.734 | €1.734 | €1.696 | 1,152 | |
| €1.733 | +0.063 | +3.8% | €1.734 | €1.734 | €1.724 | 0 | |
| €1.67 | -0.048 | -2.8% | €1.678 | €1.698 | €1.656 | 0 | |
| €1.718 | 0.00 | 0.0% | €1.718 | €1.718 | €1.715 | 0 | |
| €1.718 | -0.097 | -5.3% | €1.718 | €1.718 | €1.718 | 0 | |
| €1.815 | -0.047 | -2.5% | €1.815 | €1.815 | €1.815 | 1,030 | |
| €1.862 | -0.006 | -0.3% | €1.862 | €1.862 | €1.862 | 0 | |
| €1.868 | -0.024 | -1.3% | €1.868 | €1.868 | €1.868 | 0 | |
| €1.892 | -0.025 | -1.3% | €1.892 | €1.892 | €1.892 | 0 | |
| €1.917 | +0.023 | +1.2% | €1.917 | €1.917 | €1.917 | 0 | |
| €1.894 | +0.154 | +8.9% | €1.894 | €1.894 | €1.894 | 1,346 | |
| €1.74 | -0.126 | -6.8% | €1.844 | €1.857 | €1.722 | 0 |
- Ticker
- Frankfurt:83B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Latest deck · Aug 21, 2026
H1 2026 Earnings Presentation
Earnings · 31 slides
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 2, 2026
Closed €1.57 (+4.7%) on Nov 2, 2026
Next Day Disclosure Return
Oct 14, 2026
Closed €1.60 (-1.3%) on Oct 14, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 2, 2026
Closed €1.74 (-1.4%) on Oct 2, 2026
2026 Interim Report
Sep 30, 2026
Closed €1.79 (+4.6%) on Sep 30, 2026
3SBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 11 in the last 12 months · 32 in all · newest Nov 2, 2026 · oldest 2020
- Decks
- 27 decks · latest Aug 21, 2026
Where 3SBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:1530 三生製藥 · Home listing | HKEX | Hong Kong | HKD |
| OTC:TRSBF | OTC | United States | USD |
| gettex:83B | gettex | Germany | EUR |
| LS Exchange:A14T7Q | LS Exchange | Germany | EUR |
| Lang & Schwarz:A14T7Q | Lang & Schwarz | Germany | EUR |
| Frankfurt:83B · This page | Frankfurt | Germany | EUR |
| Munich:83B | Munich | Germany | EUR |
| Dusseldorf:83B | Dusseldorf | Germany | EUR |
| Stuttgart:83B | Stuttgart | Germany | EUR |
| Tradegate:83B | Tradegate | Germany | EUR |
Valuation
P/E 3.2× against a median of 23.6×: the lowest of 9 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $12.45B HKD
- P/E
- 3.2×
- EV/sales
- 0.6×
- EV/EBITDA
- 1.0×
- Price/book
- 1.0×
- Gross margin
- 92.4%
- Operating margin
- 59.6%
- Net margin
- 47.9%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| 3SBio, Inc. · HKEX:1530 | US$4.02B | US$1.59B | 3.2× | 0.6× | 1.0× | 1.0× | 47.9% | 0.1× | n/a |
| Ajanta Pharma Limited · NSE:AJANTPHARM | US$4.47B | US$4.42B | 32.8× | 6.6× | 16.1× | 8.5× | 20.3% | 0.0× | n/a |
| Aspen Pharmacare Holdings Limited · JSE:APN | US$4.39B | US$4.36B | 29.1× | 2.2× | 10.5× | 1.0× | 7.6% | 0.2× | n/a |
| Camurus AB · OMXSTO:CAMX | US$4.30B | US$3.88B | 58.3× | 16.4× | 42.4× | 8.8× | 31.2% | 0.0× | n/a |
| Hubei Jumpcan Pharmaceutical Co., Ltd Class A · SSE:600566 | US$4.30B | US$2.54B | 15.8× | 2.9× | n/a | 2.0× | 30.7% | 0.0× | n/a |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A · SZSE:002294 | US$4.30B | US$4.15B | n/a | n/a | n/a | 3.3× | n/a | 0.1× | n/a |
| Wockhardt Limited · NSE:WOCKPHARMA | US$3.83B | US$4.00B | 86.6× | 9.9× | 51.4× | 6.9× | 10.9% | 0.4× | n/a |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A · SZSE:002603 | US$3.72B | US$3.34B | 18.0× | 2.8× | n/a | 2.2× | 17.4% | 0.0× | n/a |
| Organon & Co. · NYSE:OGN | US$3.65B | US$10.75B | 17.1× | 1.8× | n/a | 3.1× | 3.5% | 7.2× | 0.52 |
| Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS | US$3.60B | US$3.36B | n/a | 4.9× | n/a | 34.6× | −102.9% | 0.7× | 0.62 |
| Laboratorios Farmaceuticos Rovi, S.A. · BME:ROVI | US$3.54B | US$3.52B | 17.4× | 4.2× | 15.8× | 4.6× | 23.9% | 0.1× | n/a |
| Median of the others | US$4.06B | US$3.94B | 23.6× | 4.2× | 16.1× | 4.0× | 17.4% | 0.1× | 0.57 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.30 HKD · Analysts' mean
- EPS, year to Dec 2026
- 1.02 · 3 analysts
- Revenue, year to Dec 2026
- 9.45B · 14 analysts
Team and board
| Officer | Role |
|---|---|
| Tony He | Chief Financial Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 20, 2025 · Before open | −3.4% |
| Quarter to Mar 31, 2025 | Apr 30, 2025 | +9.5% |
| Q4 2024 | Mar 25, 2025 | +1.7% |
| Quarter to Sep 30, 2024 | Nov 18, 2024 | −0.5% |
| Q2 2024 | Aug 22, 2024 | −11.0% |
| Quarter to Mar 31, 2024 | May 22, 2024 | −1.7% |
| Q4 2023 | Mar 20, 2024 | +1.3% |
| Quarter to Sep 30, 2023 | Nov 15, 2023 | +3.1% |
| Q2 2023 | Aug 24, 2023 · Before open | +2.7% |
| Q1 2023 | May 17, 2023 | −3.7% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 21, 2023 · Before open | +0.9% |
| Q3 2022 | Nov 16, 2022 | +0.1% |
| Q2 2022 | Aug 24, 2022 · Before open | +0.2% |
| Q1 2022 | May 18, 2022 | +1.4% |
| Q4 2021 | Mar 28, 2022 · After close | +4.3% |
| Q3 2021 | Nov 17, 2021 | −2.5% |
| Q2 2021 | Aug 25, 2021 · Before open | +0.1% |
| Q1 2021 | May 19, 2021 | +1.7% |
| Q4 2020 | Feb 26, 2021 · Before open | −6.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 31 slides | Aug 21, 2026 |
| FY2025 Earnings Presentation | Earnings | 31 slides | Mar 31, 2026 |
| J.P. Morgan 2026 Healthcare Conference | Conference | 30 slides | Jan 15, 2026 |
| H1 2025 Earnings Presentation | Earnings | 44 slides | Sep 1, 2025 |
| FY2024 Earnings Presentation | Earnings | 48 slides | Mar 26, 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference (January 2025) | Conference | 43 slides | Jan 16, 2025 |
| H1 2024 Earnings Presentation | Earnings | 40 slides | Aug 23, 2024 |
| FY2023 Earnings Presentation | Earnings | 46 slides | Mar 21, 2024 |
| H1 2023 Earnings Presentation | Earnings | 43 slides | Aug 24, 2023 |
| FY2022 Earnings Presentation | Earnings | 46 slides | Mar 21, 2023 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2022 Earnings Presentation | Earnings | 43 slides | Aug 25, 2022 |
| FY2021 Earnings Presentation | Earnings | 45 slides | Mar 28, 2022 |
| H1 2021 Earnings Presentation | Earnings | 48 slides | Aug 25, 2021 |
| FY2020 Earnings Presentation | Earnings | 30 slides | Mar 31, 2021 |
| H1 2020 Earnings Presentation | Earnings | 30 slides | Jul 18, 2020 |
| FY2019 Earnings Presentation | Earnings | 30 slides | Mar 31, 2020 |
| H1 2019 Earnings Presentation | Earnings | 36 slides | Aug 22, 2019 |
| FY2018 Earnings Presentation | Earnings | 36 slides | Mar 21, 2019 |
| H1 2018 Earnings Presentation | Earnings | 35 slides | August 2018 |
| FY2017 Earnings Presentation | Earnings | 36 slides | March 2018 |
| FY2016 Earnings Presentation | Earnings | 36 slides | Jun 14, 2017 |
| FY2016 Earnings Presentation | Earnings | 36 slides | Jun 13, 2017 |
| H1 2016 Earnings Presentation | Earnings | 33 slides | August 2016 |
| H1 2016 Earnings Presentation | Earnings | 33 slides | 2016 |
| H1 2015 Earnings Presentation | Earnings | 29 slides | August 2015 |
| H1 2015 Earnings Presentation | Earnings | 29 slides | 2015 |
| FY2012 Earnings Presentation | Earnings | 31 slides | Mar 18, 2013 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.7B | 9.11B | 7.82B | 6.86B | 6.38B | 5.59B | 5.32B | 4.58B | 3.73B | 2.80B |
| Cost of revenue | 1.35B | 1.28B | 1.17B | 1.19B | 1.11B | 1.06B | 925.3M | 877.3M | 676.2M | 402.3M |
| Gross profit | 16.3B | 7.83B | 6.64B | 5.67B | 5.28B | 4.52B | 4.39B | 3.71B | 3.06B | 2.40B |
| Research and development | 1.52B | 1.33B | 794.8M | 693.2M | 753.9M | 590.3M | 526.6M | 362.7M | 257.3M | 243.0M |
| Selling, general and administrative | 641.9M | 501.9M | 480.8M | 384.7M | 371.5M | 452.8M | 676.0M | 316.8M | 315.1M | 301.2M |
| Operating income | 10.5B | 2.65B | 2.46B | 2.07B | 1.83B | 1.46B | 1.34B | 1.44B | 1.16B | 908.8M |
| Depreciation and amortization | 530.4M | 394.9M | 334.8M | 368.0M | 329.0M | 360.9M | 334.0M | 313.3M | 243.7M | 161.0M |
| EBITDA | 11.1B | 3.04B | 2.79B | 2.44B | 2.16B | 1.82B | 1.67B | 1.76B | 1.40B | 1.07B |
| Interest expense | 74.4M | 190.8M | 212.3M | 102.7M | 66.5M | 81.1M | 109.5M | 138.4M | 141.3M | 147.7M |
| Income before tax | 10.7B | 2.72B | 1.98B | 2.27B | 1.87B | 979.1M | 1.22B | 1.50B | 1.10B | 850.1M |
| Income tax | 1.65B | 500.5M | 392.2M | 370.7M | 241.2M | 208.0M | 242.8M | 218.3M | 177.6M | 135.8M |
| Net income | 8.48B | 2.09B | 1.55B | 1.92B | 1.65B | 835.8M | 973.7M | 1.28B | 935.4M | 712.6M |
| Earnings per share, basic | 3.44 | 0.85 | 0.63 | 0.72 | 0.60 | 0.33 | 0.38 | 0.46 | 0.35 | 0.28 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.3B | 2.02B | 2.69B | 2.15B | 2.80B | 3.09B | 2.08B | 1.79B | 2.40B | 674.4M |
| Short-term investments | 7.41B | 3.77B | 3.30B | 4.86B | 1.90B | 1.27B | 472.2M | 68.1M | 704.6M | 362.2M |
| Receivables | 1.08B | 1.71B | 85.4M | 1.31B | 1.38B | 983.0M | 1.30B | 1.48B | 1.32B | 785.5M |
| Inventory | 1.05B | 795.2M | 777.5M | 712.2M | 690.5M | 619.5M | 528.5M | 384.6M | 376.5M | 262.4M |
| Current assets | 22.7B | 9.35B | 9.19B | 9.76B | 7.79B | 6.68B | 4.60B | 4.44B | 5.28B | 2.24B |
| Property, plant and equipment | 5.59B | 5.15B | 4.47B | 3.83B | 2.98B | 2.32B | 1.79B | 1.76B | 1.76B | |
| Goodwill | 4.17B | 4.25B | 4.20B | 4.14B | 3.84B | 3.92B | 4.15B | 4.09B | 3.92B | 4.13B |
| Total assets | 36.3B | 24.2B | 23.6B | 22.0B | 19.2B | 17.7B | 14.8B | 13.8B | 13.8B | 11.0B |
| Accounts payable | 244.8M | 179.6M | 212.1M | 249.5M | 230.4M | 203.3M | 149.8M | 112.9M | 274.6M | 58.8M |
| Current liabilities | 4.42B | 5.46B | 3.73B | 1.79B | 1.42B | 1.45B | 1.61B | 1.66B | 2.20B | 1.14B |
| Long-term debt | 723.3M | 37.6M | 2.69B | 4.07B | 2.44B | 2.51B | 2.32B | 2.72B | 3.32B | 2.54B |
| Total debt | 2.62B | 3.55B | 4.84B | 4.52B | 2.63B | 2.91B | 2.81B | 3.29B | 4.41B | 3.06B |
| Total liabilities | 5.82B | 6.18B | 7.11B | 6.59B | 4.55B | 4.58B | 4.45B | 4.93B | 6.12B | 4.27B |
| Shareholders' equity | 27.2B | 15.4B | 14.0B | 13.0B | 12.2B | 10.7B | 9.63B | 8.61B | 7.40B | 6.52B |
| Shares outstanding | 2.47B | 2.47B | 2.44B | 2.65B | 2.77B | 2.54B | 2.54B | 2.75B | 2.65B | 2.56B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9.67B | 3.20B | 2.08B | 2.18B | 1.58B | 1.34B | 1.89B | 1.15B | 1.07B | 1.00B |
| Capital spending | -541.4M | -963.2M | -704.3M | -973.7M | -1.15B | -981.5M | -486.3M | -433.4M | -243.1M | -466.0M |
| Free cash flow | 9.13B | 2.24B | 1.38B | 1.21B | 432.6M | 363.1M | 1.40B | 716.8M | 831.0M | 538.3M |
| Cash from investing | -1.83B | -1.36B | -1.35B | -3.72B | -1.29B | -1.87B | -1.13B | -405.9M | -643.2M | -4.38B |
| Cash from financing | 2.35B | -2.25B | -353.0M | 763.2M | -481.1M | 1.55B | -454.4M | -1.39B | 1.32B | 2.71B |
| Dividends paid | -559.8M | -555.1M | -224.9M | -417.1M | 0 | -16.3M | -150.8M | -150.8M | -150.8M | |
| Share buybacks | 0 | -242.4M | 337.0K | -475.7M | -412.9M | -11.2M | -38.2M | -40.6M | 0 | |
| Change in cash | 10.0B | -468.5M | 459.4M | -717.8M | -222.8M | 1.01B | 290.2M | -606.0M | 1.72B | -621.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 2, 2026 | Monthly return | HKEX |
| Next Day Disclosure Return | Oct 14, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 13, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 12, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 9, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 8, 2026 | Next day disclosure return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 2, 2026 | Monthly return | HKEX |
| 2026 Interim Report | Sep 30, 2026 | Interim report | HKEX |
| Next Day Disclosure Return | Sep 29, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Sep 28, 2026 | Next day disclosure return | HKEX |
Cap table
Built by 6ix from 3SBio, Inc.’s releases
- Common shares
- 2,476,392,002
- Fully diluted
- 2,476,392,002
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,476,392,002 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,476,392,002 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Tony He | Chief Financial Officer · Since at least Jan 21, 2025 |
Log in to ask 6ix AI your own questions about 3SBio, Inc.